LQDA catalysts
Catalysts and events linked to LQDA, newest first.
LQDA stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight Continues 2026-09-14 · Mixed | commercial cash flow risk from intellectual property dispute | Liquidia reached 5,000 Yutrepia patients but faces ongoing patent litigation with United Therapeutics. | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation Hangs 2026-09-14 · Mixed | patent litigation outcome and commercial adoption | Source details 5,000 patient milestone against 13.9% monthly drop on UTHR litigation. | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent Battle 2026-09-13 · Mixed | commercial drug uptake versus patent litigation risk | Yutrepia exceeded 5,000 patient starts as of July 2026 while LQDA faces ongoing United Therapeutics litigation. | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit 2026-09-13 · Mixed | commercial revenue ramp offset by litigation expense drag | Yutrepia reaches 5,000 patients as LQDA manages active United Therapeutics patent litigation | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Lawsuit 2026-09-13 · Mixed | patent litigation risk discounting commercial adoption cash flows | Yutrepia reached 5,000+ patients as of July 2026 while stock fell 13.9% on legal overhang. | Not recorded |
| Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighs 2026-09-12 · Mixed | commercial volume growth offset by patent litigation legal discount | Liquidia enrolled over 5,000 patients on Yutrepia while stock lost 13.9% on litigation friction. | Not recorded |
| Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation Lingers 2026-09-12 · Mixed | commercial drug adoption balanced against patent litigation risk | Yutrepia passed 5,000 patients while active patent litigation with United Therapeutics persists. | Not recorded |
| Liquidia crosses 5,000 Yutrepia patients amid United Therapeutics patent fight 2026-09-12 · Mixed | commercial volume growth offset by patent litigation legal overhang | Source notes over 5,000 patients started on Yutrepia alongside a 13.9% monthly drop due to litigation and R&D costs. | Not recorded |
Do these developments change your position?
Review LQDA alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-14Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation HangsLQDA UTHR
- 2026-09-14Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Fight ContinuesLQDA UTHR
- 2026-09-13Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics LawsuitLQDA UTHR
- 2026-09-13Liquidia Surpasses 5,000 Yutrepia Patient Starts Amid United Therapeutics Patent BattleLQDA UTHR
- 2026-09-13Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent SuitLQDA UTHR
- 2026-09-12Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation weighsLQDA UTHR
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Litigation LingersLQDA UTHR
- 2026-09-12Liquidia crosses 5,000 Yutrepia patients amid United Therapeutics patent fightLQDA UTHR
- 2026-09-12Liquidia reaches 5,000 Yutrepia patients amid United Therapeutics patent litigationLQDA UTHR
- 2026-09-12Liquidia reaches 5,000 Yutrepia patients as United Therapeutics litigation loomsLQDA UTHR
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Patent Battle PersistsLQDA UTHR
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Starts as United Therapeutics Patent Battle Weighs on StockLQDA UTHR
- 2026-09-12Liquidia Surpasses 5,000 Yutrepia Patients as United Therapeutics Litigation ContinuesLQDA UTHR
- 2026-09-12Liquidia Logs 5,000 Yutrepia Patients Amid Ongoing Litigation with UTHRLQDA UTHR
- 2026-09-12Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation loomsLQDA UTHR
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.